<DOC>
	<DOC>NCT00460187</DOC>
	<brief_summary>Multicenter, prospective, pivotal study designed to demonstrate the safety and efficacy of the Lumen Biomedical, Inc. FiberNet® Embolic Protection System as an adjunctive device during carotid artery percutaneous intervention in high surgical risk patients.</brief_summary>
	<brief_title>EPIC US Pivotal Study</brief_title>
	<detailed_description />
	<criteria>One or more of the high surgical risk criteria. Symptomatic with atherosclerotic stenosis ≥ 50% or asymptomatic with atherosclerotic stenosis ≥ 70% of the carotid artery by NASCET Criteria. Prior stenting of ipsilateral carotid. Planned treatment of contralateral carotid within 30 days. Experienced a myocardial infarction within the last 14 days. Undergone an angioplasty or PTCA/PTA procedure within the past 48 hours. Undergone cardiac surgery within the past 60 days. Suffered a stroke within the past 14 days. Suffered a transient ischemic neurological attack (TIA) or amaurosis fugax within the past 48 hours. Abnormal baseline blood counts; platelets &lt;50,000 or &gt;700,000/mm3 or WBC count &lt; 3 x103/uL. Intracranial stenosis that exceeded the severity of an extracranial stenosis. Total occlusion of the target vessel. Lesion within 2cm of the ostium of the common carotid artery. A stenosis that is known to be unsuitable for stenting Serial lesions that requires more than one stent to cover entire lesion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>carotid artery, distal protection device, carotid stenting</keyword>
</DOC>